McClellan Applauds Passage of TRANQ Research Act

Washington, D.C. – Yesterday, the House considered and passed H.R. 1734, the TRANQ Research Act, as amended by the Senate. This bill was introduced by Research and Technology Subcommittee Chairman Mike Collins (R-GA) and Congresswoman Yadira Caraveo (D-CO). Earlier this year, Rep. McClellan was an original cosponsor of H.R. 1734 when it passed unanimously in the House Committee on Science, Space and Technology. The bill now goes to President Biden's desk for signature. 

The TRANQ Research Act directs the National Institute of Standards and Technology (NIST) to deepen its partnerships and strategically focus on the science needed to detect, identify, and better understand synthetic opioids. The usage of one particularly dangerous fentanyl analogue known as “tranq” is skyrocketing across the country and contributing to an ever-growing number of drug overdoses. Also known as the “Zombie Drug”, tranq contains xylazine—a veterinary tranquilizer— and has gruesome side effects, causing large wounds that won’t heal, and is resistant to standard opioid overdose treatments.  

“With the growing concern surrounding fentanyl usage and a staggering rise in drug overdoses, it is crucial we continue to rally bipartisan support to address these issues. This epidemic cannot continue to be ignored,” said Congresswoman McClellan. “The TRANQ Research Act helps develop our understanding of synthetic opioids and other harmful drugs by raising awareness of this ongoing issue and instructing the National Institute of Standards and Technology (NIST) to strengthen its research initiatives and partnerships. Addiction does not discriminate, so we must continue to provide support and resources for those who are struggling.” 

Read the bill, as amended here. You can reach the American Addiction Centers’ Fentanyl Addiction Hotline here.